Intra-Cellular Therapies
ITCI
$72.13
Share price
-1.35%
Change (1 day)
18.65%
Change (1 year)
Categories
Intra-Cellular Therapies (ITCI) - Total debt
Total debt on the balance sheet as of December 2023 : $16.93 M
According to Intra-Cellular Therapies's latest financial reports the company's total debt is $16.93 M. A company’s total debt is the sum of all current and non-current debts.
Intra-Cellular Therapies - Total debt on balance sheet (from 2013 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $16.93 M | -15.48% |
| 2022-12-31 | $20.04 M | -21.12% |
| 2021-12-31 | $25.4 M | -12.82% |
| 2020-12-31 | $29.14 M | 25.92% |
| 2019-12-31 | $23.14 M | |
| 2018-12-31 | $N/A |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | $83.43 M | 392.58% | 🇺🇸 USA |
 MediciNova MNOV | $0.21 M | -98.73% | 🇺🇸 USA |
 Curis CRIS | $2.79 M | -83.50% | 🇺🇸 USA |